What is the recommended door to needle time for fibrinolysis in ACS?

What is the recommended door to needle time for fibrinolysis in ACS?

• A. 15 minutes
• B. 30 minutes
• C. 60 minutes
• D. 90 minutes

Answer: (B)

The recommended door to needle time for administering fibrinolysis in patients with acute coronary syndrome (ACS) is ideally within 30 minutes. This time frame is critical as it has been associated with improved outcomes in terms of mortality and reduction of myocardial damage. Fibrinolytic therapy is most effective when given as soon as possible after the onset of symptoms, particularly within the first few hours. Delays in treatment can lead to worse patient outcomes due to prolonged ischemia of the myocardium. The 30-minute benchmark allows healthcare providers enough time for initial assessment and administration of the necessary interventions without unduly delaying treatment, thus optimizing the clinical benefits of fibrinolysis. Adherence to this timeline is encouraged to align with guidelines and standards established by cardiology organizations, which emphasize rapid diagnosis and treatment in ACS cases.

The recommended door to needle time for administering fibrinolysis in patients with acute coronary syndrome (ACS) is ideally within 30 minutes. This time frame is critical as it has been associated with improved outcomes in terms of mortality and reduction of myocardial damage.

Fibrinolytic therapy is most effective when given as soon as possible after the onset of symptoms, particularly within the first few hours. Delays in treatment can lead to worse patient outcomes due to prolonged ischemia of the myocardium. The 30-minute benchmark allows healthcare providers enough time for initial assessment and administration of the necessary interventions without unduly delaying treatment, thus optimizing the clinical benefits of fibrinolysis.

Adherence to this timeline is encouraged to align with guidelines and standards established by cardiology organizations, which emphasize rapid diagnosis and treatment in ACS cases.